Diomune was founded in 2009 as a spin-off from the Centro de Biología Molecular Severo Ochoa (CBMSO), born from an idea of Dr. Manuel Fresno, a prestigious immunologist with over 30 years of experience. Diomune originated with the development of new molecular modeling strategies combined with genetic searches that led to the identification of new compounds with immunomodulatory properties and great potential for the treatment of several autoimmune diseases.
Since its conception, the company has been part of the Parque Científico at the Universidad Autónoma of Madrid and has received strong financial support from the Centro de Desarrollo y Tecnología Industrial (CDTI).
With the support of a prestigious multinational company, Diomune developed and brought to market a novel autovaccine for treatment of canine leishmaniasis in 2012, which contributes to the treatment of a great number of animals throughout Spain.
Currently, Diomune is gathering the financial resources needed to conduct a human clinical trial and launch compound IV1303, a drug with more than 50% efficacy in the treatment of septic patients.
We would like to mention that Diomune executes its research projects thanks to granted public proposals, equity, and benefits obtained through the external R & D services we offer.